Dermira Inc (DERM.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||2014||Chairman of the Board, Chief Executive Officer, Co-Founder|
|40||2017||Senior Vice President - Corporate Development and Strategy, Founder|
|54||2016||Co-Founder, Chief Development Officer|
|48||2017||Chief Financial Officer, Chief Operating Officer|
|40||2016||Chief Commercial Officer|
- BRIEF-Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate
- BRIEF-Dermira and UCB agree to end collaboration agreement for Cimzia
- BRIEF-Dermira highlights new long-term safety data for glycopyrronium tosylate
- BRIEF-Dermira completes patient enrollment in two phase 3 trials of olumacostat glasaretil for the treatment of acne vulgaris
- BRIEF-New CIMZIA findings presented at European Academy Of Dermatology And Venereology (EADV) Congress